Trials / Completed
CompletedNCT00322686
Study of Oglemilast for the Treatment of Asthma
Efficacy and Safety of Oglemilast in the Prevention of Allergen-induced Bronchospasm
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oglemilast | Oglemilast, 15mg oral administration, once per day and then dose-matched placebo |
| DRUG | Placebo then Oglemilast | Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day. |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2006-12-01
- First posted
- 2006-05-08
- Last updated
- 2012-03-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00322686. Inclusion in this directory is not an endorsement.